GLP1R and infarction: In fact, the results revealed that GLP-1 administered before ischemia led to a significant reduction in infarction compared with an inhibitor of its breakdown or saline groups, whereas GLP-1 receptor antagonist exendin (9–39) appears to inhibit the action of GLP-1; several multiple pro-survival kinases are essential for cardioprotection mediated by GLP-1 (cAMP inhibitor Rp-cAMP and PI3K inhibitor LY294002 and by the p44/42 mitogen-activated protein kinase inhibitor UO126) [25].